Sorrento Therapeutics (NSDQ:SRNE) subsidiary Scilex Pharmaceuticals touted data today from a head-to-head clinical adhesion study of its ZTlido lidocaine patch, comparing it to the EU reference product, Versatis. ZTlido is a lidocaine patch in development for the treatment of post-herpetic neuralgia – a severe neuropathic pain condition that affects elderly people and patients who have […]
Clinical Trials
Study: Personalized coaching no better than standard treatment for Type II diabetes
A study published online last week in the Journal of the American Medical Assn. showed no benefit for lifestyle coaching over standard medical treatment in Type II diabetes in a real-world setting. Researchers at the University of North Carolina randomized 450 Type II diabetics between January 2014 and July 2015 to 1 of 3 treatment arms: […]
Medtronic touts retrospective data in Reactive ATP therapy AF study
Medtronic‘s (NYSE:MDT) today released data from a retrospective analysis of patients with its Reactive ATP therapy, touting slowed atrial fibrillation progression for individuals with implanted cardiac devices. Data came from a retrospective analysis of approximately 8,800 patients and was presented at the EHRA Europace-Cardiostim 2017 meeting, Fridley, Minn.-based Medtronic said. “Atrial fibrillation can be a debilitating […]
Gamida Cell lands $40m for late-stage NiCord trial
Gamida Cell said today that it raised $40 million to support the ongoing Phase III trial of its NiCord cell graft and expand its in-house manufacturing capacity. The private financing was led by new investor Shavit Capital. VMS Investment Group and Israel Biotech Fund joined existing investor Novartis in the round, as well as Clal Biotechnology […]
Study: Ekos ultrasound device provides relief to patients with chronic deep vein thrombosis
BTG (LON:BTG) touted data last week showing that patients with chronic deep vein thrombosis and post-thrombotic syndrome can be safely and effectively treated with the Ekos device and anti-coagulation drugs. The study’s protocol is the 1st treatment regimen proven to reduce the symptoms of PTS and demonstrate an improvement in quality of life for patients […]
FDA clears IND for Cerveau’s tau imaging agent
Cerveau Technologies said today that the FDA cleared the investigational new drug application for its tau imaging agent. The company plans to work with pharmaceutical partners to evaluate the product’s use in positron emission tomography scans to assess neurofibrillary tangles in the brain. NFTs composed of aggregated tau protein are characteristic of certain neurodegenerative conditions like […]
Blaze Bioscience touts Phase 1 data from pediatric oncology Tumor Paint BLZ-100 study
Oncology-focused biotech company Blaze Bioscience today released clinical data from the Phase 1 study of its Tumor Paint BLZ-100 in pediatric brain cancer patients, touting that the agent was well tolerated. Data from the study was presented at the 4th Biennial Pediatric Neuro-Oncology Basic and Translational Research Conference in New York. Read the whole story […]
Sanofi, Parexel collaborate on clinical trial data collection wearables
Parexel said today it is collaborating with Sanofi (NYSE:SNY) to develop and promote wearable devices to improve collection of data during clinical trials. Through the collaborative deal, the 2 companies will leverage their specific expertise to explore how wearables could improve study performance and new drug development and how sensors from several wearable devices could be […]
BrainScope touts data from trial of BrainScope One EEG-based brain index
BrainScope today touted results from a study of its EEG-based Brain Function Index, part of its BrainScope One device, which demonstrated a “significant relationship” between BFI readings and the severity of functional impairment in mild head injuries. The study was published in the Journal of Neurotrama this month, the Bethesda, Md.-based company said. The company’s BrainScope […]
pSivida implant meets primary endpoint in late-stage trial
pSivida (NSDQ:PSDV) touted data from the 2nd Phase III trial of its Durasert 3-year treatment for posterior segment uveitis. The company reported that the trial, which followed patients for 3 years, met its primary endpoint of prevention of recurrence of posterior uveitis at 6 months. In the 153-patient trial, 21.8% of Durasert-treated patients had a […]
Adapt Pharma touts usability data for Narcan nasal spray
Adapt Pharma touted data today from 2 human factors studies that evaluated the usability of its Narcan nasal spray by adolescents and people with low literacy. The Dublin-based company’s product is a ready-to-use, needle-free device that delivers a single dose of naloxone in a nasal spray to someone experiencing an opioid overdose and does not require […]